Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121930 | 0.92 | GHSR (0.52) | GHSRPLA2G4ATDP2NSD2CASP3 | |
| SCHEMBL1709543 | 0.91 | GHSR (0.57) | GHSRCCR4KMT2AMEN1 | |
| SCHEMBL10121949 | 0.90 | GHSR (0.63) | GHSR | |
| SCHEMBL10121669 | 0.88 | GHSR (0.61) | GHSRPLA2G4ATDP2NSD2CASP3 | |
| SCHEMBL1709712 | 0.87 | GHSR (0.53) | GHSRCCR4TP53KMT2AMEN1 | |
| SCHEMBL10121934 | 0.85 | GHSR (0.54) | GHSRPLA2G4ACCR4TP53 | |
| SCHEMBL1988495 | 0.84 | GHSR (0.62) | GHSRCCR4TP53KMT2AMEN1 | |
| SCHEMBL1709599 | 0.83 | GHSR (0.56) | GHSRCCR4KMT2AMEN1 | |
| SCHEMBL10121951 | 0.83 | GHSR (0.62) | GHSR | |
| SCHEMBL1709601 | 0.81 | GHSR (0.54) | GHSRCCR4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885PLA2G4A 1602/4885TDP2 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.